According to Zacks, “Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company’s product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts. “
Several other equities research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Stealth BioTherapeutics in a research note on Tuesday, October 8th. Cantor Fitzgerald initiated coverage on Stealth BioTherapeutics in a research note on Friday, September 27th. They issued an “overweight” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $22.43.
Stealth BioTherapeutics (NASDAQ:MITO) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. On average, analysts anticipate that Stealth BioTherapeutics will post -0.14 EPS for the current fiscal year.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Recommended Story: How does a 12b-1 fee affect fund performance?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.